Inclusion Criteria:  Participants inadequately controlled on diet and exercise. Participants inadequately controlled on metformin alone. Participants inadequately controlled on pioglitazone alone. Participants inadequately controlled on metformin and pioglitazone combination therapy. Participants switching from alogliptin co-administered with pioglitazone.  Exclusion Criteria:  Participants treated with study drug outside of the locally approved label in Korea. Participants with contraindication for the use of study drug (as described in the Korean product label).